Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
Total Valuation
Indaptus Therapeutics has a market cap or net worth of $4.47M. The enterprise value is $6.43M.
Market Cap$4.47M
Enterprise Value$6.43M
Share Statistics
Indaptus Therapeutics has 1,751,163 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,751,163
Owned by Insiders3.83%
Owned by Institutions1.08%
Financial Efficiency
Indaptus Therapeutics’s return on equity (ROE) is -3.81 and return on invested capital (ROIC) is -381.38%.
Return on Equity (ROE)-3.81
Return on Assets (ROA)-2.05
Return on Invested Capital (ROIC)-381.38%
Return on Capital Employed (ROCE)-3.90
Revenue Per Employee0.00
Profits Per Employee-2.15M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Indaptus Therapeutics is ―. Indaptus Therapeutics’s PEG ratio is 1.17.
PE Ratio―
PS Ratio0.00
PB Ratio55.92
Price to Fair Value55.92
Price to FCF-17.90
Price to Operating Cash Flow-0.09
PEG Ratio1.17
Income Statement
In the last 12 months, Indaptus Therapeutics had revenue of 0.00 and earned -15.02M in profits. Earnings per share was -1.61.
Revenue0.00
Gross Profit0.00
Operating Income-15.37M
Pretax Income-15.02M
Net Income-15.02M
EBITDA-15.37M
Earnings Per Share (EPS)-1.61
Cash Flow
In the last 12 months, operating cash flow was -15.52M and capital expenditures 0.00, giving a free cash flow of -15.52M billion.
Operating Cash Flow-15.52M
Free Cash Flow-15.52M
Free Cash Flow per Share-8.86
Dividends & Yields
Indaptus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.13
52-Week Price Change-89.58%
50-Day Moving Average2.63
200-Day Moving Average8.09
Relative Strength Index (RSI)54.38
Average Volume (3m)1.08M
Important Dates
Indaptus Therapeutics upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Indaptus Therapeutics as a current ratio of 1.95, with Debt / Equity ratio of -2.05%
Current Ratio1.95
Quick Ratio1.95
Debt to Market Cap0.00
Net Debt to EBITDA0.38
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Indaptus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Indaptus Therapeutics EV to EBITDA ratio is -14.31, with an EV/FCF ratio of -17.44.
EV to Sales0.00
EV to EBITDA-14.31
EV to Free Cash Flow-17.44
EV to Operating Cash Flow-17.44
Balance Sheet
Indaptus Therapeutics has $5.83M in cash and marketable securities with $8.69K in debt, giving a net cash position of $5.82M billion.
Cash & Marketable Securities$5.83M
Total Debt$8.69K
Net Cash$5.82M
Net Cash Per Share$3.32
Tangible Book Value Per Share$0.42
Margins
Gross margin is 50.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin50.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Indaptus Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside292.16% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast34.57%